Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

5-Day Gavage Study of 4-Methylcyclohexanemethanol (CASRN: 34885-03-5) in Male Harlan Sprague Dawley Rats

ABSTRACT: The goal of this study was to characterize the potential toxicity and genomic benchmark dose of 4-methylcyclohexylmethanol in liver and kidney of male Harlan Sprague Dawley rats using a 5 day dose-response toxicogenomics study design. The 5 day study is used to quickly identify the dose levels where changes in molecular pathways occur. These dose level where pathway level effects begin to occur have been shown to provide a close approximation of a no effect dose level from more resource intensive guideline toxicological assessments.

ORGANISM(S): Rattus norvegicus

PROVIDER: GSE75657 | GEO | 2015/12/31

SECONDARY ACCESSION(S): PRJNA304989

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

5-Day Gavage Study of Crude 4-Methylcyclohexanemethanol in Male Harlan Sprague Dawley Rats

2015-12-31 | GSE75655 | GEO

5-Day Gavage Study of 4-Methylcyclohexanemethanol (CASRN: 34885-03-5) in Male Harlan Sprague Dawley Rats

Project description:The goal of this study was to characterize the potential toxicity and genomic benchmark dose of 4-methylcyclohexylmethanol in liver and kidney of male Harlan Sprague Dawley rats using a 5 day dose-response toxicogenomics study design. The 5 day study is used to quickly identify the dose levels where changes in molecular pathways occur. These dose level where pathway level effects begin to occur have been shown to provide a close approximation of a no effect dose level from more resource intensive guideline toxicological assessments. A total of 58 samples were evaluated in this study. 29 were from liver and 29 were from kidney. Five biological replicate were obtained for the 0 mg/kg/day control group for both liver and kidney. All other non-zero dose groups contain 4 biological replicates. The control groups for liver and kidney are the 0 mg/kg dose groups for those organs.

2015-12-31 | E-GEOD-75657 | biostudies-arrayexpress

5-Day Gavage Study of Propylene glycol phenyl ether (PPH; CASRN 770-35-4) in Male Harlan Sprague Dawley Rats

2015-12-31 | GSE75656 | GEO

5-Day Gavage Study of Propylene glycol phenyl ether (PPH; CASRN 770-35-4) in Male Harlan Sprague Dawley Rats

Project description:The goal of this study was to characterize the potential toxicity and genomic benchmark dose of propylene glycol phenyl etherl in liver and kidney of male Harlan Sprague Dawley rats using a 5 day dose-response toxicogenomics study design. The 5 day study is used to quickly identify the dose levels where changes in molecular pathways occur. These dose level where pathway level effects begin to occur have been shown to provide a close approximation of a no effect dose level from more resource intensive guideline toxicological assessments. A total of 49 samples were evaluated in this study. 25 were from liver and 24 were from kidney. Five biological replicate were obtained for the 0 mg/kg/day control group for both liver and kidney. All other non-zero dose groups contain 4 biological replicates. The control groups for liver and kidney are the 0 mg/kg dose groups for those organs.

2015-12-31 | E-GEOD-75656 | biostudies-arrayexpress

5-Day Gavage Study of Crude 4-Methylcyclohexanemethanol in Male Harlan Sprague Dawley Rats

Project description:The goal of this study was to characterize the potential toxicity and genomic benchmark dose of crude 4-methylcyclohexylmethanol in liver and kidney of male Harlan Sprague Dawley rats using a 5 day dose-response toxicogenomics study design. The 5 day study is used to quickly identify the dose levels where changes in molecular pathways occur. These dose level where pathway level effects begin to occur have been shown to provide a close approximation of a no effect dose level from more resource intensive guideline toxicological assessments. A total of 44 samples were evaluated in this study. 27 were from liver and 17 were from kidney. Signficant batch effects were detected with a subset of samples and these were removed from the study prior to data analysis and are therefore not included in this GEO series. 3 (kidney) or 4 (liver) biological replicate were obtained for the 0 mg/kg/day control group for both liver and kidney. All other non-zero dose groups contain 2-4 biological replicates. The groups that contain only 2 or 3 replicates do so due to a number of samples not passing QC as byproduct of batch effects. The control groups for liver and kidney are the 0 mg/kg dose groups for those organs.

2015-12-31 | E-GEOD-75655 | biostudies-arrayexpress

5 Day Oral Study of A-998679 in Male Sprague Dawley Rats (Jejunum)

Project description:Male Sprague-Dawley rats [Crl:CD®(SD)IGS BR], weighing ~250 g at study initiation were obtained from Charles River Laboratories, Inc. (Wilmington, MA). Rats were housed singly in ventilated, stainless steel, wire-bottom hanging cages and fed non-certified Rodent Chow (Harlan Labs, Madison, WI) and water ad libitum and acclimated for at least 5 days after arrival. Rats were randomly assigned to various treatment groups (3 rats/group) and were dosed once daily by oral gavage with vehicle (0.2% hydroxypropylmethylcellulose at a dose volume of 10 ml/kg) or with 30, 100, or 200 mg/kg of A-998679. All rats were fasted overnight after their last dose, weighed and sacrificed under isoflurane anesthesia. Liver and small intestine (jejunum) were flash frozen in liquid nitrogen and stored at −80°C until processing for gene expression profiling on the Affymetrix platform.

2012-08-04 | GSE39850 | GEO

5 Day Oral Study of A-998679 in Male Sprague Dawley Rats (liver)

2012-07-24 | GSE39525 | GEO

The Chronic Gavage Toxicity/Carcinogenicity Study of Indole-3-Carbinol (I3C) in Harlan Sprague-Dawley Rats (G823524-B), CAS No 700-06-1

Project description:Indole-3-carbinol is used as a dietary supplement and has potential use as a therapeutic agent for the prevention of various types of cancer. While substantial evidence exists that indole-3-carbinol can reduce the risk of cancers induced by several known carcinogens when administered to animals, indole-3-carbinol can also function as an initiator and tumor promoter in certain models. The carcinogenic potential of indole-3-carbinol has not been studied in a 2-year bioassay. The objective of the microarray study was to evaluate the transcriptional changes in liver from rats exposed to 0 or 300 mg/kg indole-3-carbinol. At 3 months, livers were analyzed from female Harlan Sprague Dawley rats in the 2-year gavage study of indole-3-carbinol.

2014-07-17 | GSE59287 | GEO